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Surgical TechniquesDISCUSSION
Nafamostat mesilate has been used as an anticoagulant in
substitution for heparin in the situations of CPB, left ventric-
ular assist devices, and hemodialysis. The main advantages
of nafamostat mesilate are its short half-life and its function-
ing to inactivate coagulation, fibrinolysis, and platelet
aggregation.Murase and colleagues8 demonstrated that nafa-
mostat mesilate inhibits fibrinolysis, preserves platelet func-
tion during CPB, and reduces blood loss. Ota and associates9
demonstrated successful CPBmanagement with mesilate for
3 patients with recent intracranial hemorrhage. Both groups
emphasized that inhibition of fibrinolysis activation was the
most important supplementary effect of nafamostat mesilate,
because as excessive fibrinolysis can cause intracranial
bleeding during and after CPB.8,9 On the other hand,
heparin enhances fibrinolytic activity during CPB, leading
to dissolution of clots and recurrence of bleeding. In this
study we demonstrated successful CPB management with
a continuous infusion of nafamostat mesilate in open heart
surgical procedures for patients after acute stroke.
Some authors have maintained that low-dose heparin
can achieve adequate anticoagulation during CPB, but Ov-
rum and coworkers2 reported that clot formation in the
cardiotomy reservoir occurred during CPB with low-
dose heparin. In our opinion, low-dose heparinization
during CPB should not be routinely used because of the
risk of clot formation; however, it provides an advantage
for patients with the risk of bleeding. We believe that
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dose heparin.
Limitations to the current study include small sample
size, the lack of a control group, the lack of data on fibrino-
lysis, and the study’s retrospective nature. Further prospec-
tive analysis is needed to confirm the advantage of our CPB
strategy with low-dose heparin and nafamostat mesilate for
patients with bleeding risks.
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Interact Cardiovasc Thorac Surg. 2007;6:270-3.Transcatheter aortic valve implantation combined with conventional
heart surgery: Hybrid approach for complex cardiac
pathologic featuresMiralem Pasic, MD, PhD, Semih Buz, MD, Axel Unbehaun, MD, and Roland Hetzer, MD, PhD, Berlin,
GermanyA new hybrid approach, the combination of transcatheter
aortic valve implantation (TAVI) and conventional cardiacsurgery, might be a possible solution for patients considered
not suitable for complex conventional surgery. We have
summarized our preliminary experience.1-3
BRIEF CLINICAL REPORT
From April 2008 to October 2011, 11 patients underwent
simultaneous conventional cardiac surgery and TAVI with
or without additional percutaneous coronary intervention
(PCI) (Table 1). Ten patients had severe aortic valve steno-
sis, and one (patient 11) had pure insufficiency. The com-
bined procedure was the first heart operation in 6 patients,
the second in 3 patients, the third in 1 patient, and the fourth
in 1 patient.ery c September 2012
TABLE 1. Patient and procedural parameters
Pt.
no.
Age
(y)
EuroSCORE
(%)
STS score
(%)
LVEF
(%)
Main reason for
hybrid procedure
Surgery type
combined with TAVI
CPB time
(min)
Crossclamp time
(min)
Median
sternotomy
1 72 50.8 21.4 30 Comorbidities LV aneurysmectomy 0 0 No (redo)
2 69 26.9 5.9 20 Porcelain aorta CABG (LITA to LAD) 0 0 Yes
3 62 46.3 18.5 35 Comorbidities LV aneurysmectomy 0 0 No (redo)
4 70 50.2 12.9 50 Shock Tricuspid valve repair 123 0 No (redo)
5 86 79.5 28.9 60 Porcelain aorta Tricuspid valve repair 150 0 Yes
6 85 42.8 10.7 50 Frailty LV aneurysmectomy 0 0 No
7 89 53.9 24.1 35 Frailty Tricuspid valve replacement,
CABG (SVG to RCA)
172 0 Yes
8 84 84.9 22.9 20 Myocardial failure CABG (LITA to LAD), PCI
(CX and RCA)
0 0 Yes
9 43 57.9 8.7 35 Porcelain aorta Mitral valve replacement 77 0 Yes (second redo)
10 93 28.5 13.8 55 Frailty LV aneurysmectomy, PCI
(LAD and CX)
0 0 No
11 40 19.4 3.3 55 Porcelain aorta Redo-CABG (LITA to LAD) 131 60 Yes (third redo)
Pt. no., Patient number; EuroSCORE, European System for Cardiac Operative Risk Evaluation; STS, Society of Thoracic Surgeons; LVEF, left ventricular ejection fraction; TAVI,
transcatheter aortic valve implantation; CPB, cardiopulmonary bypass; LV, left ventricular; CABG, coronary artery bypass grafting; LITA, left internal thoracic artery; LAD, left
anterior descending (coronary artery); SVG, saphenous vein graft; RCA, right coronary artery; PCI, percutaneous coronary intervention; CX, circumflex coronary artery.
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FIGURE 1. ‘‘Valve-in-homograft’’ transapical aortic valve implantation (TAVI) combined with mitral valve replacement on the beating heart. Patient 9
with homograft degeneration in the aortic position (‘‘porcelain aorta’’) (A) and severe mitral valve regurgitation (B). Angiography confirmed optimal
‘‘valve-in-homograft’’ position of the transcatheter aortic valve prosthesis without any paravalvular leakage (C). Fluoroscopy (D), transesophageal echo-
cardiography (E), and computed tomography (F) showing both newly implanted prostheses. The patient’s risk profile was extremely high owing to his pre-
operative condition, including asthenia secondary to congestive heart failure, chronic obstructive pulmonary disease, pulmonary hypertension (95/65 mm
Hg), liver cirrhosis, portal hypertension, ascites, a previous splenorenal shunt, a history of bleeding from esophageal varices, and chronic anemia. His med-
ical history included a diagnosis of Marfan syndrome, composite graft replacement of the ascending aorta and aortic valve for type A dissection 12 years
previously, and redo surgery for prosthetic valve endocarditis with aortic annular abscess treated with aortic homograft implantation 6 years previously. AH,
Aortic homograft; RC, right coronary artery; LM, left main coronary artery; LV, left ventricle.
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Surgical TechniquesThe surgical access for the combined procedures was ei-
ther standard median sternotomy (6 patients) or left ante-
rior minithoracotomy (4 patients; Table 1). One patient
(patient 4) with previous cardiac surgery underwent
TAVI through a left anterior minithoracotomy and addi-
tional tricuspid valve repair through a right anterior
thoracotomy.
TAVI was combined with mitral valve replacement in 1
patient (Figure 1), tricuspid valve repair in 2, tricuspid valve
replacement and coronary artery bypass grafting (CABG) in
1, left ventricular aneurysmectomy in 3, left ventricular
aneurysmectomy and PCI in 1, CABG in 1, redo CABG
in 1, and CABG and PCI in 1. Normothermic cardiopulmo-
nary bypass (CPB) was used in 5 patients with aortic cross-
clamping in only 1 (crossclamp time, 60 minutes). The
mean CPB time was 120  31 minutes (range, 77–172
minutes; Table 1). The median procedural time (‘‘skin-to-
skin’’) was 266 minutes (interquartile range, 155–395 min-
utes). Transapical TAVI4,5 with balloon-expandable valves
(Edwards Sapien THV; Edwards Lifesciences, Irvine, Ca-
lif) was performed in 10 patients and open, direct trans-
aortic repeat TAVI6 in 1 (patient 11) for technical surgical
reasons after previous ‘‘valve in valve’’ TAVI in a degener-
ated homograft. If median sternotomy was used for the
combined procedure, the transapical TAVI procedure was
slightly modified with regard to the placement of the 14F
and 26F introducers. They were forwarded through
a 1-cm incision below the left costal arch into the pericar-
dium toward the apex and then through the apex into the
left ventricular cavity.1 This approach enabled us to leave
the enlarged heart in situ without the need to mobilize it.
Additionally, access to the aortic valve is direct and without
any need for curving or angulation of the axis from the apex
to the ascending aorta. Otherwise, because of the rigid intro-
ducers, the heart would have had to be mobilized and dis-
placed from the pericardium.1 Coronary artery disease, if
present, was treated simultaneously by CABG or PCI.2 If
used, PCI was performed as the last procedure using trans-
femoral access.2
The technical success of the combined procedures was
100%, with no intraoperative mortality or procedural com-
plications. Also, no 30-day mortality or in-hospital mortal-
ity occurred. Of the 11 patients, 7 had an uneventful
postoperative course and 4 developed postoperative compli-
cations. The mean follow-up was 14  12 months. All pa-
tients improved, with all patients in New York Heart
Association functional class I to II. No paravalvular leakage
developed during follow-up and no new neurologic events
occurred. During the follow-up period, 1 patient (patient
8) developed prosthetic valve endocarditis 3 months after
TAVI that was successfully treated with antibiotics. Three
noncardiac-related deaths occurred (patients 1, 5, and 7 at730 The Journal of Thoracic and Cardiovascular Surg7, 10, and 2 months postoperatively, respectively), for over-
all follow-up survival of 73%.
DISCUSSION
Our preliminary results from an extremely heteroge-
neous group of patients showed that a combined proce-
dure (TAVI with standard cardiac surgery) is possible
and safe. Replacing conventional aortic valve surgery
with TAVI in a complex surgical procedure might enable
the treatment of patients who would otherwise not be el-
igible for complex conventional surgery. Depending on
the type of surgical procedure, the hybrid approach could
shorten or eliminate aortic crossclamping or even waive
the need for CPB. The avoidance of aortic crossclamping
(or keeping the aortic crossclamp time as short as possi-
ble) precludes or reduces global myocardial ischemia in
serious conditions. The hybrid approach avoids extensive
surgical dissection in patients with previous cardiovascu-
lar procedures. Therefore, the combined approach offers
easier intraoperative management and faster postoperative
recovery of the patients. This hybrid concept using a trans-
catheter biologic prosthetic valve could be applied in
younger polymorbid patients with a reduced life expec-
tancy (eg, patient 9) or patients who choose a biologic
valve because of their occupational requirements or a pri-
vate lifestyle with possible detrimental effects of antico-
agulant therapy (eg, patient 11). In the future, if the
prosthetic valve degenerates, the ‘‘valve-in-valve’’ con-
cept using simple repeat TAVI performed using either
the transfemoral or transapical approach—an easy techni-
cal procedure—could be applied (with no additional risk
if prospective definitive surgery should be needed).
The new hybrid approach and the unification of the sur-
gical way of thinking with the experience of interventional
cardiologists opens up a new treatment strategy for very
high-risk patients with complex cardiac problems. It can
be expected that in the future these new types of hybrid pro-
cedures will be more frequently applied for complex path-
ologic features of the heart or redo surgery.
The other members of our TAVI team were Thorsten Drews,
MD, Stephan Dreysse, MD, Giuseppe D’Ancona, MD, PhD, Mar-
ian Kukucka, MD, Alexander Mladenow, MD, Guna Tetere, MD,
Tom Gromann, MD, Ekatarina Ivanitskaia-K€uhn, MD, Christoph
Klein, MD, Katrin Sch€afer, and Natalia Solowjowa, MD.We thank
Anne Gale for editorial assistance and Rosemarie G€unther for sec-
retarial help.
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837-9.Warm beating heart with deep hypothermic circulatory arrest:
A technique for an unclampable aorta with aortic valve regurgitationZain Khalpey, MD, PhD, MRCS,a,b Rene J. Dekkers, CCP,a,b Foeke J. H. Nauta, MD,a,b and
Prem Shekar, MD,a,b Boston, MassThe presence of severe aortic insufficiency (AI) in pa-
tients with severe atherosclerotic disease of the ascending
aorta at aortic valve replacement (AVR) poses consider-
able technical challenges, often associated with poor out-
comes.1,2 Furthermore, the risk of cerebral embolus
precludes the use of an aortic crossclamp.1 The use of
deep hypothermic circulatory arrest increases overall
safety; however, it is associated with an increased risk
of neurologic complications.3
We report a technique applied to 2 patients in which the
heart was kept warm and beating in normal sinus rhythm
while systemically cooling the body and organs. This strat-
egy attempts to eliminate the ventricular fibrillation associ-
ated with hypothermia, avoiding left ventricular distension
and endocardial ischemia, without clamping the aorta.METHODS
After systemic heparinization, we cannulated the right axillary artery
with an 8-mm Hemashield graft (Boston Scientific, Boston, Mass), con-
nected to a 3/83 3/8 straight connector (Sorin Group, Arvada, Colo). Ve-
nous cannulation consisted of a 21F 60-cm Biomedicus (Medtronic,
Minneapolis, Minn) femoral venous cannula placed percutanously into
the right femoral vein and a single-stage malleable cannula placed into
the superior vena cava (Medtronic). Cardiopulmonary bypass (CPB) was
initiated. To prevent distension, both patients had a vent placed in the right
superior pulmonary vein just after initiating CPB and before systemic cool-
ing began. A retrograde coronary sinus cannula, either the Gundryretrograde cannula (Medtronic) or the Edwards Life Science RC 2014 (Ed-
wards Life Science, Irvine, Calif) was placed into the coronary sinus di-
rectly with echocardiographic assistance. The Sorin BCD Vanguard
cardioplegia system (Sorin Group) was used to administer warm (37C)
pump blood at 300 mL/min into the coronary sinus. The retrograde circuit
pressures reached 175mmHg, and coronary sinus pressures of 30 to 40mm
Hg were maintained while the patients were being cooled.
Systemic cooling with a 10 to 12C gradient to 22 to 20C was initi-
ated with the Maquet Heater-Cooler Unit HCU 30 Dual Heater Cooler
(MAQUET Cardiovascular, Wayne, NJ).
Below arterial 32C, an effort was made to safely decrease the CPB flow
and thus the circuit line pressure, decreasing the incidence of competitive
cold antegrade blood from the CPB in-flow cannula.
When the patient venous line and nasopharyngeal temperatures equal-
ized at 22C to 20C, 30 mM of systemic potassium was administered
into the CPB pump to arrest the heart. The heart rate before potassium ad-
ministration was bradycardic (22–30 beats/min), normal sinus rhythm.
Cold blood cardioplegia was administered to arrest the heart for the rest
of the operation in an antegrade or retrograde route as per standard
techniques.RESULTS
Both patients underwent successful AVR and replace-
ment of the ascending aorta. The duration of sinus bradycar-
dia until cardiac arrest (ie, time of systemic cooling) was 60
and 65 minutes followed by potassium administration at
22.4C at 20.0C, respectively. There was no operativemor-
tality, and postoperatively, the patients showed no signs of
neurologic sequelae.DISCUSSION
This technique can be considered an alternative for pa-
tients in who aortic crossclamping is unsafe and might oth-
erwise be inoperable.
Constant coronary perfusion, particularly in patients with
hypertrophied ventricles,4 while maintaining sinus rhythm
and cardiac contractions is crucial for optimal myocardial
protection.5rdiovascular Surgery c Volume 144, Number 3 731
